Raise closed, search for fresh raises on Seedstage

Westlake Village, CA

Expanding topical formula applications to address eczema and toenail fungus through clinical trials.

• Mission: Expanding the applications of its FDA-cleared topical formula, Hexagen, to provide non-invasive treatment options for eczema and toenail fungus.  
• Innovation: Leveraging patented PermaFusion drug delivery technology to enhance the effectiveness and safety of topical treatments for dermatological conditions, offering an alternative to injectable biologics and steroids.  
• Market Opportunity: Targeting high-need markets by addressing unmet medical needs in skin health, particularly for eczema and toenail fungus, with a proven track record in over 200,000 clinical uses.  
• Funding Uses: Supporting clinical trials, regulatory efforts, and operational growth to bring expanded dermatology applications to market and meet increasing demand.  
• Strategic Positioning: Positioned to revolutionize the dermatology space with safe, effective, and non-invasive solutions for common skin conditions, backed by strong clinical safety and efficacy data.  
• Social Impact: Committed to advancing healthcare by offering alternative, safer treatments for skin conditions, reducing reliance on invasive and potentially harmful therapies.

Turn Therapeutics is raising funds to expand its FDA-cleared topical formula, Hexagen, into new applications for eczema and toenail fungus treatment, aiming to address high-need markets with non-invasive therapeutic options. Initially developed to combat advanced wounds and infections, Hexagen has been successfully applied in over 200,000 cases without adverse events, establishing a strong safety profile and efficacy that Turn now seeks to leverage for broader dermatological needs. The company’s formula targets inflammatory triggers in conditions like eczema, potentially offering an alternative to current treatments that rely on injectable biologics and steroids, which can have adverse side effects.

This fundraising effort will primarily support clinical trials and regulatory efforts, allowing Turn Therapeutics to gather the necessary data to bring these expanded applications to market. Additionally, Turn plans to support operational growth to meet demand as it enters new segments of the dermatology market. Through this campaign, Turn Therapeutics offers investors the opportunity to participate in a mission-driven company committed to advancing safe, effective care solutions in wound and skin health.

Company Info

Turn Therapeutics focuses on innovative treatments for skin and wound care using patented drug delivery technology.

Turn Therapeutics is a pharmaceutical and medical device company that specializes in advanced wound care and dermatologic treatments, particularly focusing on conditions such as eczema and onychomycosis. The company has developed a patented drug delivery technology called PermaFusion, which allows for deeper penetration of active ingredients in topical treatments while minimizing the amount needed, thereby reducing potential side effects. Their flagship formula has been FDA cleared for various indications, demonstrating efficacy against a range of skin disorders. Turn Therapeutics aims to redefine treatment standards by providing innovative solutions that prioritize safety and effectiveness. With a commitment to addressing unmet medical needs, the company is exploring additional therapeutic applications for its technology, which has already seen over 200,000 uses in clinical settings. The founder’s personal experiences with infection and healing have driven the mission of the company to innovate in the field of skin and wound care.